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lowing three criteria: 1) diagnosis of diabetes mellitus; 2) pre-
scription of oral anti-diabetic drug; and 3) fasting blood or
plasma glucose value indicative of diabetes. The average length
of follow-up upon inclusion was 4.5 years. METHODS: Costs
of inpatient care were estimated by classifying hospitalisations
of study patients into diagnosis-related groups (DRGs) accord-
ing to the Nord-DRG classiﬁcation system and assigning average
costs per DRG (2002 prices) according to a national list relying
on individual patient level costs incurred at Swedish hospitals
applying the Nord-DRG system. Costs of outpatient care were
estimated by assigning unit costs of outpatient care-giver con-
tacts obtained from published sources to data on study patients’
care-giver contacts as recorded in medical records at participat-
ing primary care centres. RESULTS: The average annual cost of
inpatient care over the studied years was €1088 per patient (SD
€4460; n = 9292 on average). Between 2000 and 2004, an annual
increase in costs of between 9% and 15% was observed (con-
stant prices). The average annual cost of outpatient care during
the studied years was €363 per patient (SD €437) with little vari-
ation over the years. GP visits accounted for 40% of outpatient
costs, the average patient making 1.7 GP visits per year. CON-
CLUSIONS: Diabetes continues to impose a heavy economic
burden on society. Cost estimates from this population-based
sample of Swedish diabetic patients may serve as reference values
for a Swedish setting.
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OBJECTIVES: The RESULT study demonstrated that sulphony-
lurea (SU) plus rosiglitazone (RSG) provided a sustained and
substantial increase in beta-cell function (BCF) from baseline
(56%, p < 0.0001) compared to SU alone (6%, p = 0.41). This
modelling study explores the impact on disease progression,
health outcomes and health care expenditure in Portugal of 
different approaches to modelling RSG’s effect on BCF.
METHODS: DiDACT, a peer-reviewed published long-term
model of T2DM, was used to replicate patient characteristics
(73% Male, mean age 68.2 years, mean BMI 30 kg/m2) and the
impact of SU + RSG on BCF observed in the RESULT study using
an additive, a multiplicative or combined approach. Disease pro-
gression for 1000 hypothetical patients, projected total lifetime
health care costs and health gains, measured in time to insulin
and quality-adjusted life years (QALYs) were predicted. Follow-
ing failure of intermediate SU dose to maintain glycaemic target,
up-titrated SU therapy was compared to SU + RSG combination.
The treatment change threshold was HbA1C ≥ 7.5%. Resources
were valued using national unit costs from a variety of sources.
Costs and outcomes were discounted at 5% per year. RESULTS:
Both revised calibrations yielded lower lifetime health care costs
and additional QALYs, compared to the original calibration.
Compared with SU alone both revised calibrations resulted in
lower incremental cost-effectiveness ratios (ICERs). Each repre-
sentation of RSG showed greater time to insulin than SU alone
(13 years); the additive approach substantially extended viabil-
ity of oral therapy to 27.5 years compared to 20 years for mul-
tiplicative and original calibrations. CONCLUSIONS: Each
modelling approach resulted in reduced costs, increased QALYs
and time to insulin when compared with the original calibration.
The use of RSG in the management of T2DM appears to be cost-
effective in all scenarios investigated. Forthcoming long-term
studies of RSG may conﬁrm the impact of RSG on BCF observed
and enable determination of the most appropriate method for
model calibration.
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OBJECTIVES: The co-epidemics of obesity and type II diabetes
and associated complications result in an increasing population
with high risk of serious morbidity, mortality and reduced
quality of life. This analysis has been speciﬁcally developed to
estimate the cost per quality adjusted life year (QALY) gained
with orlistat compared to standard clinical practice (SCP) in a
particularly high-risk diabetic population with morbid obesity
(BMI > 35 kg/m2 and at least one additional CVD risk). In
Norway this is a population with clearly unmet needs for pre-
ventive medical interventions. METHODS: The incremental
cost-utility is calculated in an Excel-model comparing 1 year of
orlistat treatment followed by 9 years of SCP with 10 years of
SCP. The baseline risk is based on the ﬁndings of the UK Pre-
ventive Diabetes Study (UKPDS), adjusted for differences in
BMI. The effects of orlistat and SCP (conservatively assumed
equal to placebo + SCP) on risk factors (BMI, HbA1c, LDL-cho-
lesterol, SBP), are based on results from the relevant randomized
clinical trials. 3 years catch-up of risks after termination of orli-
stat is assumed. UKPDS and the Heart Protection Study provide
assessments of the change in risk associated with change in
HbA1c and the other relevant risk factors. Effects on utility are
based on the results from CODE-2. Direct costs related to the
treatment alternatives and their associated complications are
included from a Norwegian societal perspective. RESULTS: The
expected incremental cost of treating high-risk Norwegian dia-
betic morbid obese patients with orlistat is approximately
€3125/QALY. Extensive one- and multiway sensitivity analyses
using Monte Carlo simulation indicate robustness of the results.
CONCLUSIONS: The results of this model indicate that one
year treatment with orlistat is a highly cost-effective alternative
to SCP for diabetic patients with morbid obesity and additional
CVD risk in Norway.
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OBJECTIVE: To evaluate the inﬂuence of inadequate glycemic
control (IC) in comorbidity and health resource utilization of
type 2 diabetic patients treated in a general practitioner setting.
METHODS: Retrospective observational study (systematic-sam-
pling) of patients older than 18 years, treated in 5 primary care
centres during 2005. The following parameters were evaluated:
IC, deﬁned by HbA1c > 7%; age; sex; comorbidities (hyperten-
sion, hypercholesterolemia, smoking, obesity, ischemic-heart-
disease, cardiovascular event (CVE), COPD, depression,
cardiac-renal-hepatic insufﬁciency, microvascular complica-
tions); clinical parameters (BMI, total-cholesterol, LDL-Friede-
